tradingkey.logo

Sanofi SA

SNY
View Detailed Chart

47.030USD

-0.620-1.30%
Close 09/12, 16:00ETQuotes delayed by 15 min
114.48BMarket Cap
11.38P/E TTM

Sanofi SA

47.030

-0.620-1.30%
Intraday
1m
30m
1h
D
W
M
D

Today

-1.30%

5 Days

+1.14%

1 Month

-4.10%

6 Months

-18.56%

Year to Date

-2.49%

1 Year

-17.68%

View Detailed Chart

TradingKey Stock Score

Currency: USD Updated2025-09-12

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a weak stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking
59 / 176
Overall Ranking
178 / 4724
Industry
Pharmaceuticals

Support & Resistance

No Data

Score Analysis

Current score
Previous score

Analyst Rating

Based on 10 analysts
Buy
Current Rating
63.674
Target Price
+35.39%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks
Sanofi SA is a France-based healthcare company based in France. The Company focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme.
High Dividend
The company is a high dividend payer, with the latest dividend payout ratio of 171.67%.
Stable Dividend
The company has regularly paid dividends over the past 5 years, with the latest dividend payout ratio of 171.67%.
Undervalued
The company’s latest PE is 11.71, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 264.33M shares, decreasing 5.11% quarter-over-quarter.
Held by Van Duyn Dodge & E. Morris Cox
Star Investor Van Duyn Dodge & E. Morris Cox holds 71.72M shares of this stock.

News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Company

Sanofi SA is a France-based healthcare company based in France. The Company focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme.
Ticker SymbolSNY
CompanySanofi SA
CEOMr. Paul Hudson, Ph.D.
Websitehttps://www.sanofi.com/
KeyAI